Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 30-May-24 6:22 PM View:  | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 30-May-24 | Disposition | 3,045,650 | $30.00 | $91,369,600.00 | (100%) 3.05M to 0 | |
| 30-May-24 6:22 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 30-May-24 | Disposition | 3,274,300 | $30.00 | $98,229,000.00 | (100%) 3.27M to 0 | |
| 03-Jun-24 5:55 PM View: | Viking Global Investors Lp 10% Owner | Inhibrx, Inc. (INBX) | 30-May-24 | Disposition (other) | 7,150,830 | $30.00 | $214,524,992.00 | (100%) 7.15M to 0 | |
| 30-May-24 6:21 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 30-May-24 | Disposition | 2,055,550 | $30.00 | $61,666,600.00 | (100%) 2.06M to 0 | |
| 30-May-24 6:22 PM View: | Forsyth Douglas Director | Inhibrx, Inc. (INBX) | 30-May-24 | Disposition | 598,257 | $30.00 | $17,947,700.00 | (100%) 598.26K to 0 | |
| 30-May-24 6:21 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 28-May-24 | Market Sale | 300,000 | $34.30 | $10,290,000.00 | (13%) 2.36M to 2.06M | (11%) |
| 30-Aug-23 8:44 PM View: | Viking Global Investors Lp 10% Owner | Inhibrx, Inc. (INBX) | 28-Aug-23 | Private Purchase | 511,627 | $19.35 | $9,899,980.00 | 8% 6.64M to 7.15M | |
| 02-Mar-23 4:17 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 01-Mar-23 | Sale (Planned) | 40,000 | $24.21 | $968,231.00 | (2%) 2.4M to 2.36M | |
| 01-Mar-23 4:41 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 28-Feb-23 | Sale (Planned) | 60 | $25.02 | $1,501.25 | (< 1%) 3.05M to 3.05M | |
| 02-Feb-23 7:26 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 02-Feb-23 | Sale (Planned) | 11,250 | $25.45 | $286,355.00 | (< 1%) 2.41M to 2.4M | |
| 02-Feb-23 7:26 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 01-Feb-23 | Sale (Planned) | 28,750 | $24.73 | $710,856.00 | (1%) 2.44M to 2.41M | |
| 24-Jan-23 6:46 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 24-Jan-23 | Sale (Planned) | 4,335 | $25.72 | $111,478.00 | (< 1%) 3.05M to 3.05M | |
| 24-Jan-23 6:46 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 23-Jan-23 | Sale (Planned) | 21,665 | $25.36 | $549,364.00 | (< 1%) 3.07M to 3.05M | |
| 23-Jan-23 6:10 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 23-Jan-23 | Sale (Planned) | 9,500 | $25.26 | $239,999.00 | (< 1%) 3.28M to 3.27M | |
| 04-Jan-23 5:53 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 04-Jan-23 | Sale (Planned) | 7,105 | $23.48 | $166,829.00 | (< 1%) 2.44M to 2.44M | |
| 04-Jan-23 5:53 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 03-Jan-23 | Sale (Planned) | 32,895 | $23.77 | $781,770.00 | (1%) 2.48M to 2.44M | |
| 22-Dec-22 4:04 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 21-Dec-22 | Sale (Planned) | 9,500 | $27.02 | $256,679.00 | (< 1%) 3.29M to 3.28M | |
| 20-Dec-22 4:59 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 19-Dec-22 | Sale (Planned) | 26,000 | $25.56 | $664,443.00 | (< 1%) 3.1M to 3.07M | |
| 07-Dec-22 4:30 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 06-Dec-22 | Sale (Planned) | 40,000 | $27.22 | $1,088,680.00 | (2%) 2.52M to 2.48M | |
| 22-Nov-22 4:42 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 21-Nov-22 | Sale (Planned) | 9,500 | $29.89 | $283,972.00 | (< 1%) 3.3M to 3.29M | |
| 18-Nov-22 5:06 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 17-Nov-22 | Sale (Planned) | 26,000 | $27.88 | $724,910.00 | (< 1%) 3.12M to 3.1M | |
| 02-Nov-22 5:04 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 01-Nov-22 | Market Sale (Planned) | 40,000 | $33.51 | $1,340,390.00 | (2%) 2.56M to 2.52M | (14%) |
| 24-Oct-22 4:36 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 21-Oct-22 | Sale (Planned) | 9,500 | $30.13 | $286,232.00 | (< 1%) 3.31M to 3.3M | |
| 18-Oct-22 4:37 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 17-Oct-22 | Sale (Planned) | 26,000 | $29.59 | $769,443.00 | (< 1%) 3.15M to 3.12M | |
| 12-Oct-22 4:39 PM View: | Viking Global Investors Lp 10% Owner | Inhibrx, Inc. (INBX) | 07-Oct-22 | Private Purchase | 1,333,330 | $30.00 | $39,999,900.00 | 25% 5.31M to 6.64M | |
| 05-Oct-22 4:15 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 04-Oct-22 | Sale (Planned) | 40,000 | $27.82 | $1,112,810.00 | (2%) 2.6M to 2.56M | |
| 14-Sep-22 4:09 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 13-Sep-22 | Gift | 160,000 | -- | -- | 6% 2.6M to 2.76M | |
| 14-Sep-22 4:09 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 13-Sep-22 | Gift | 160,000 | -- | -- | (6%) 2.76M to 2.6M | |
| 07-Sep-22 4:57 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 06-Sep-22 | Sale (Planned) | 40,000 | $14.91 | $596,274.00 | (2%) 2.64M to 2.6M | |
| 25-Aug-22 4:20 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 24-Aug-22 | Gift | 11,900 | -- | -- | (< 1%) 3.32M to 3.31M | |
| 08-Aug-22 4:22 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 05-Aug-22 | Gift | 3,400 | -- | -- | (< 1%) 3.33M to 3.32M | |
| 04-Aug-22 4:33 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 03-Aug-22 | Sale (Planned) | 15,500 | $18.47 | $286,209.00 | (< 1%) 2.65M to 2.64M | |
| 02-Aug-22 4:52 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 02-Aug-22 | Gift | 50,000 | -- | -- | 1% 3.4M to 3.45M | |
| 02-Aug-22 4:52 PM View: | Kayyem Jon Faiz Director | Inhibrx, Inc. (INBX) | 02-Aug-22 | Gift | 118,500 | -- | -- | (3%) 3.45M to 3.33M | |
| 04-Aug-22 4:33 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 02-Aug-22 | Sale (Planned) | 24,500 | $17.70 | $433,626.00 | (< 1%) 2.68M to 2.65M | |
| 08-Jul-22 4:03 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 07-Jul-22 | Sale (Planned) | 40,000 | $17.17 | $686,800.00 | (1%) 2.72M to 2.68M | |
| 07-Apr-22 4:11 PM View: | Eckelman Brendan P. Chief Scientific Officer | Inhibrx, Inc. (INBX) | 05-Apr-22 | Sale (Planned) | 400 | $25.04 | $10,016.00 | (< 1%) 2.72M to 2.72M | |
| 24-Mar-21 7:12 PM View: | Eckelman Brendan P. Chief Scientific Officer Director | Inhibrx, Inc. (INBX) | 24-Mar-21 | Market Sale (Planned) | 17,000 | $19.02 | $323,340.00 | (< 1%) 2.73M to 2.72M | 5% |
| 18-Feb-21 5:06 PM View: | Wagner Klaus W. Chief Medical Officer | Inhibrx, Inc. (INBX) | 17-Feb-21 | Market Sale (Planned) | 19,559 | $25.29 | $494,647.00 | (8%) 234.71K to 215.15K | 29% |
| 18-Feb-21 5:06 PM View: | Wagner Klaus W. Chief Medical Officer | Inhibrx, Inc. (INBX) | 16-Feb-21 | Market Sale (Planned) | 156,474 | $24.32 | $3,805,450.00 | (40%) 391.18K to 234.71K | 26% |
| 18-Feb-21 5:08 PM View: | Eckelman Brendan P. Chief Scientific Officer Director | Inhibrx, Inc. (INBX) | 16-Feb-21 | Market Sale (Planned) | 17,000 | $25.90 | $440,300.00 | (< 1%) 2.75M to 2.73M | 30% |
| 19-Jan-21 4:10 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 28-Dec-20 | Gift | 500,000 | -- | -- | 16% 3.15M to 3.65M | |
| 19-Jan-21 4:10 PM View: | Lappe Mark Chief Executive Officer Director | Inhibrx, Inc. (INBX) | 28-Dec-20 | Gift | 500,000 | -- | -- | (14%) 3.65M to 3.15M | |
| 19-Jan-21 4:16 PM View: | Eckelman Brendan P. Chief Scientific Officer Director | Inhibrx, Inc. (INBX) | 04-Dec-20 | Gift | 160,000 | -- | -- | 6% 2.67M to 2.83M | |
| 19-Jan-21 4:16 PM View: | Eckelman Brendan P. Chief Scientific Officer Director | Inhibrx, Inc. (INBX) | 04-Dec-20 | Gift | 160,000 | -- | -- | (6%) 2.83M to 2.67M | |
| 28-Aug-20 4:29 PM View: | Viking Global Investors Lp 10% Owner | Inhibrx, Inc. (INBX) | 26-Aug-20 | Purchase | 180,219 | $18.92 | $3,409,870.00 | 4% 5.13M to 5.31M | |
| 25-Aug-20 7:47 PM View: | Viking Global Investors Lp 10% Owner | Inhibrx, Inc. (INBX) | 25-Aug-20 | Purchase | 85,304 | $19.36 | $1,651,690.00 | 2% 5.04M to 5.13M | |
| 25-Aug-20 7:47 PM View: | Viking Global Investors Lp 10% Owner | Inhibrx, Inc. (INBX) | 24-Aug-20 | Purchase | 46,161 | $19.43 | $897,000.00 | < 1% 4.99M to 5.04M | |
| 24-Aug-20 4:31 PM View: | Ra Capital Management, LLC 10% Owner | Inhibrx, Inc. (INBX) | 21-Aug-20 | Conversion | 2,129,000 | -- | -- | 100% 0 to 2.13M | |
| 21-Aug-20 4:24 PM View: | Forsyth Douglas Director | Inhibrx, Inc. (INBX) | 21-Aug-20 | Conversion | 82,422 | -- | -- | 16% 515.84K to 598.26K |
